Rekombinanter CLDN18.2 (Zolbetuximab Biosimilar) Antikörper
Kurzübersicht für Rekombinanter CLDN18.2 (Zolbetuximab Biosimilar) Antikörper (ABIN7795131)
Target
Antikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Güteklasse
-
-
Expressionssystem
- Mammalian cells
-
Verwendungszweck
- Zolbetuximab Biosimilar, Claudin 18.2 Monoclonal Antibody
-
Produktmerkmale
- What is zolbetuximab biosimilar research grade? Zolbetuximab is a humanized monoclonal antibody directed against the human protein Claudin 18.2 (the isoform 2 of Claudin), and potentially used for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. Zolbetuximab is an Fc-engineered, humanized, monoclonal antibody (IgG1κ isotype). Zolbetuximab biosimilar uses the same protein sequences as the potential therapeutic antibody zolbetuximab . Claudin-18 in humans is a protein encoded by the CLDN18 gene. The CLDN18 protein belongs to the large claudin family of proteins, which form tight junction strands in epithelial cells. Isoform 2 (Claudin 18.2) is abundant in gastric tumors.
-
Aufreinigung
- Protein A or G affinity column
-
Reinheit
- >95 % by reducing SDS-PAGE
-
Endotoxin-Niveau
- < 1 EU per 1 mg of the protein by the LAL method
-
Immunogen
- Human Claudin 18.2
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- > 3 mg/mL
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- CLDN18.2 (Zolbetuximab Biosimilar)
-
Andere Bezeichnung
- Zolbetuximab Biosimilar
-
Substanzklasse
- Biosimilar
Target
-